A combination of mineral, vitamin, and active vitamin-form nutrients within one pharmaceutical dose form, the combination of elements. The formulation development program ensures accurate ingredient content, desirable tablet properties, and suitable finished product attributes.
This combination brings together Calcium Carbonate, Vitamin D3, Methylcobalamin, L-Methylfolate Calcium & Pyridoxal-5-Phosphate. These ingredients have vastly differing physical-chemical properties, contents, and processing characteristics, requiring formulation development criteria around raw-material quality, compatibility, blending, compression, and stability.
Formulation development of this combination will satisfy the range of nutrients with low-volume dose form ingredients for companies developing a diverse portfolio of nutrient/supplement/potency variations across a wide PCD Pharma Franchise portfolio of products. This combination can complement single-ingredient nutrients, other combination dosage forms, and other pharmaceutical formats such as softgel, capsule, and syrup for established nutraceutical and nutritional franchise operators.
Calcium Carbonate (Matter Mineral Element) can influence powder-flow, bulk-density, and compression characteristics when used at high-concentrations. Raw-material quality can therefore influence finished-product characteristics and properties, requiring powder flow and particle size determination during pre-formulation studies for repeatable results.
Vitamin D3 (Cholecalciferol) is a fat-soluble vitamin, and accurate control of content, incorporation, and stability through careful formulation support will be necessary to achieve homogeneity and stability.
Methylcobalamin (Vitamin B12: methylcobalamin) can influence content-uniformity with low dose concentration, requiring weighted dosing, premix-mixing, and representative sampling to achieve B2B quality. This vitamin B12 form can be low-dose, and require handling during formulation development.
L-Methylfolate Calcium (Folate-Constituent Element) can also be low-dose, and optimize the powder blend-content uniformity through compatibility studies with the other combination ingredients.
Pyridoxal-5-Phosphate (Vitamin B6: active form) will contribute physical-chemical interaction considerations when finalizing the formulation.
Suitable pharmaceutical excipients for the formulation may include excipients such as lubricants, glidants, preservatives, binders, matrix agents, diluents, and others as necessary.
Calcium Carbonate, Vitamin D3, Methylcobalamin, L-Methylfolate Calcium & Pyridoxal-5-Phosphate Tablets Powder receipt, sampling, ID, specification and testing are specified for raw-material release. Only product that passes specifications will be released for manufacturing.
Powder-Fed ingredients, especially low-dose elements such as methylcobalamin, L-methylfolate calcium, and Pyridoxal-5-Phosphate require premixing or controlled-ingredient addition to ensure uniform batch content.
Process parameters should be determined around the Powder-Blend content, physical-chemistry, technology of choice, and equipment. Sifting, pre-blend, mixing, granulation-drying, milling, and final blending may be employed.
Compression may use established techniques to achieve hardness, weight, and dimension targets. Compression, capacity, and weight controls can ensure repeatability for a tablet blend under controlled compression parameters such as force and speed, and tableting weight and thickness.
Optionally, film-coating can be undertaken to final specifications. Checks include mix-content uniformity, powder characteristics, final weight uniformity, and final weight, thickness, and hardness.
Calcium Carbonate, Vitamin D3, Methylcobalamin, L-Methylfolate Calcium & Pyridoxal-5-Phosphate Tablets Quality control analysis of the ingredients and the final product should include parameters such as appearance, ID, uniformity, assay, dissolution, weight, thickness, hardness, and other individual quality requirements. Batch blend-content uniformity, in-process weights, hardness, and appearance can be specified for trending through the production process.
Sampling for vitamins can include batch content uniformity validation. Sampling plans and testing for low-dose elements such as methylcobalamin, pyridoxal-5-phosphate, and L-methylfolate calcium should follow appropriate guidelines.
The product batch report, identifying test results for both raw-materials and finished product, should include the batch analysis, traceability records, and final release documentation.
Stability study design is undertaken around the key parameters of visual appearance, assay, content uniformity, powder-flow, assay, degradation-by-products, disintegration, dissolution, physical integrity, and packaging compatibility for combinations of vitaminess, minerals, API, and excipients. The interaction of potencies, packaging systems, environment, and aging parameters can be investigated to inform packaging material selection.
Vitamin D3, together with the other vitamin ingredients, can need protection from environmental conditions, requiring suitable packaging selection. Suitable commercially available packaging or packaging-material combinations may include alu-alu, alu-pe, peel pack or strip systems, bottles, or folded packaging depending on the formulation design. Packages should be capable of protecting the product from moisture, oxygen, and other risks of degradation.
Package testing can include peel or peel-through protection, material integrity, visual inspecion, content uniformity in the package, count-verification, label inspection, and traceability.
Calcium Carbonate, Vitamin D3, Methylcobalamin, L-Methylfolate Calcium & Pyridoxal-5-Phosphate Tablets can be included in a wide range of PCD Pharma Franchise formulating nutritional vitamin/mineral/active component combinations. This combination applies to nutraceutical or nutritional supplements as a PCD Package or as a label for a manufacturing product.
Multiple research and development options exist across a range of input ingredients, formats, strengths, and combinations. The combination form can support formulation, manufacturing, testing, and quality control. Tablets can be part of a product series with the other ingredients, and in capsule or softgel form, and create a defined section of a broader franchise pharmaceutical range.
We combine quality, innovation, and strong distribution to help our partners grow successfully in the pharma market.
The company is offering business opportunity for scalable and sustainable returns to its associates. We are engaged in discovery, development and commercialization of pharmaceutical medicine keeping in mind its quality and affordability.
© Novolilly 2025. All Rights Reserved – Developed & Managed By Kavir Infotech